Hyperacute lung rejection in the pig-to-human model 4: Evidence for complement and antibody independent mechanisms

Transplantation

Volumn 79, Issue 6, 2005, Pages 662-671

  Pfeiffer, Steffen ^a,b   Zorn III, George L ^a   Blair, Kelly S A ^a   Farley, Steve M ^a   Wu, Guosheng ^a,c   Schuurman, Henk Jan ^d   White, David J G ^e   Azimzadeh, Agnes M ^a,c   Pierson III, Richard N ^a,c,f  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b KLINIKUM NÜRNBERG   (Germany)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d Immerge Biotherapeutics Inc   (United States)

^e ROBARTS RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Antibodies; Complement; Human decay accelerating factor; Hyperacute lung rejection; Transgenics; Xenografts; Xenotransplantation

Indexed keywords

ANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C3B RECEPTOR; DECAY ACCELERATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; GRAFT SURVIVAL; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERACUTE GRAFT REJECTION; LUNG GRAFT REJECTION; LUNG PERFUSION; LUNG VASCULAR RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; SWINE; TRANSGENIC ANIMAL; XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; ANTIBODIES; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; GRAFT SURVIVAL; HISTAMINE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG TRANSPLANTATION; MODELS, IMMUNOLOGICAL; PERFUSION; SWINE; THROMBOXANES; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 16244417766     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000148922.32358.BF     Document Type: Article

References (21)

1. Pfeiffer S, Zorn GL, III, Kelishadi S, et al. Role of anti-Gal alpha13Gal and anti-platelet antibodies in hyperacute rejection of pig lung by human blood. Ann Thorac Surg 2001; 72: 1681.
2. Pierson RN, III, Kasper-Konig W, Tew DN, et al. Hyperacute lung rejection in a pig-to-human transplant model: the role of anti-pig antibody and complement. Transplantation 1997; 63: 594.
3. Macchiarini P, Oriol R, Azimzadeh A, et al. Evidence of human non-alpha-galactosyl antibodies involved in the hyperacute rejection of pig lungs and their removal by pig organ perfusion. J Thorac Cardiovasc Surg 1998; 116: 831.
4. Lau CL, Daggett WC, Yeatman MF, et al. The role of antibodies in dysfunction of pig-to-baboon pulmonary transplants. J Thorac Cardiovasc Surg 2000; 120: 29.
5. Yeatman M, Daggett CW, Parker W, et al. Complement-mediated pulmonary xenograft injury: studies in swine-to- primate orthotopic single lung transplant models. Transplantation 1998; 65: 1084.
6. Kozlowski T, Ierino FL, Lambrigts D, et al. Depletion of anti-Gal(alpha) 1-3Gal antibody in baboons by specific alpha-Gal immunoaffinity columns. Xenotransplantation 1998; 5: 122.
7. Brenner P, Hinz M, Huber H, et al. The influence of antibody and complement removal with a Ig-Therasorb column in a xenogeneic working heart model. Eur J Cardiothorac Surg 1999; 15: 672.
8. Azimzadeh A, Zorn GLI, Blair KS, et al. Hyperacute lung rejection in the pig-to-human model. 2. Synergy between soluble and membrane complement inhibition. Xenotransplantation 2003; 10: 120.
9. Daggett CW, Yeatman M, Lodge AJ, et al. Total respiratory support from swine lungs in primate recipients. J Thorac Cardiovasc Surg 1998; 115: 19.
10. Bhatti FN, Schmoeckel M, Zaidi A, et al. Three-month survival of hDAF transgenic pig hearts transplanted into primates. Transplant Proc 1999; 31: 958.
11. Charreau B, Menoret S, Tesson L, et al. Protection against hyperacute xenograft rejection of transgenic rat hearts expressing human decay accelerating factor (DAF) transplanted into primates. Mol Med 1999; 5: 617.
12. Cozzi E, Tucker AW, Langford GA, et al. Characterization of pigs transgenic for human decay-accelerating factor. Transplantation 1997; 64: 1383.
13. Blum MG, Collins BJ, Chang AC, et al. Complement inhibition by FUT-175 and K76-COOH in a pig-to-human lung xenotransplant model. Xenotransplantation 1998; 5: 35.
14. Collins BJ, Blum MG, Parker RE, et al. Thromboxane mediates pulmonary hypertension and lung inflammation during hyperacute lung rejection. J Appl Physiol 2001; 90: 2257.
15. Zhang JP, Blum MG, Chang AC, et al. Immunohistologic evaluation of mechanisms mediating hyperacute lung rejection, and the effect of treatment with K76-COOH, FUT-175, and and- Gal column immunoadsorption. Xenotransplantation 1999; 6: 249.
16. Catella F, FitzGerald GA. Measurement of thromboxane metabolites by gas chromatography-mass spectrometry. Methods Enzymol 1990; 187: 42.
17. Azimzadeh A, Romain N, Vermot-Desroches C, et al. Antibodies to human adhesion molecules and von Willebrand factor: in vitro cross-species reactivity in the xenotransplantation setting. Xenotransplantation 1998; 5: 284.
18. Schröder C, Pfeiffer S, Wu G, et al. Effect of C1 Esterase Inhibition on Survival of h-DAF PIG Lungs perfused with human Blood. J Heart Lung Transplant 2003; 22: 1365.
19. Zaidi A, Schmoeckel M, Bhatti F, et al. Life-supporting pig-to-primate renal Xenotransplantation using genetically modified donors. Transplantation 1998; 65: 1584.
20. Zorn GL, III, Pfeiffer S, Azimzadeh A, et al. Thrombin inhibition protects the pulmonary xenograft from hyperacute rejection. Surgical Forum 2000; XLXI: 338.
21. Pfeiffer S, Zorn GL, III, Zhang JP, et al. Hyperacute lung rejection in the pig-to-human model. 3. platelet receptor inhibitors synergistically modulate complement activation and lung injury. Transplantation 2003; 75: 953.